Scholar Rock Q4 2019 Earnings Report
Key Takeaways
Scholar Rock reported a net loss of $51.0 million for the year ended December 31, 2019. The company's cash, cash equivalents, and marketable securities totaled $157.4 million as of December 31, 2019.
Initiated the Phase 1 proof-of-concept clinical trial of SRK-181 in patients with locally advanced or metastatic solid tumors.
On track to report interim safety and efficacy data from the TOPAZ Phase 2 clinical trial of SRK-015 in patients with Type 2 and Type 3 Spinal Muscular Atrophy in mid-2020.
Achieved First Milestone of $25 Million in Strategic Fibrosis Collaboration with Gilead Sciences.
A $25 million payment was received in January 2020 from Gilead for the achievement of the preclinical milestone under the strategic fibrosis-focused collaboration.